Search the Newsreel

Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study

This article provides an update on several biopharma companies. Summit Therapeutics has released new data for its cancer immunotherapy ivonescimab, which shows improved survival rates in lung cancer patients, addressing investor skepticism. Celldex Therapeutics' autoimmune drug barzolvolimab failed a mid-stage trial for prurigo nodularis …

Stifel Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $68

Stifel has maintained its Buy rating on Celldex Therapeutics (CLDX.US) and reiterated a target price of $68. This indicates continued confidence from Stifel in the company's performance and future prospects.

Celldex Stands By Barzolvolimab in CSU After Prurigo Nodularis Miss

Celldex maintains confidence in its drug barzolvolimab for Chronic Spontaneous Urticaria (CSU) despite a recent trial failure in Prurigo Nodularis. The company's stance follows a previous study miss for the drug in August 2025. This article highlights Celldex's continued commitment to barzolvolimab for CSU.

Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study

Celldex Therapeutics has discontinued its Phase 2 clinical trial for barzolvolimab in prur

Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss

Celldex Therapeutics announced it is discontinuing the development of barzolvolimab for prurigo nodularis (PN) after the drug failed to meet primary and secondary endpoints in a Phase 2 trial. Despite the drug effectively depleting mast cells, it did not significantly improve itch or skin …

Celldex Therapeutics, Inc. (CLDX) Stock Analysis: A Biotech Gem with 64% Potential Upside

Celldex Therapeutics, Inc. (CLDX) is a biopharmaceutical company specializing in treatments for inflammatory, allergic, and autoimmune diseases, boasting a market cap of $2.78 billion. Despite currently being unprofitable, indicated by a negative Forward P/E ratio, analysts forecast a 64.31% potential upside with an average …

Cantor Fitzgerald Issues Pessimistic Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock Price

Celldex's Barzolvolimab Fails To Meet Key Goals In Phase 2 Study For Prurigo Nodularis; Stock Down

(RTTNews) - Celldex (CLDX) reported topline results from the Phase 2 study of Barzolvolimab in Prurigo Nodularis or PN, indicating that the study did not meet the primary endpoint and key secondary endpoints. Following the results, Celldex will discontinue the Phase 2 study in …

Celldex stock falls after phase 2 trial misses key endpoints By Investing.com

Celldex Therapeutics shares dropped 13% after the company announced that its Phase 2 study of barzolvolimab for prurigo nodularis failed to meet its primary and key secondary endpoints. Despite demonstrating profound mast cell depletion, the drug did not improve itch or skin lesions compared …

Celldex Drug Depleted Mast Cells but Did Not Ease PN Itch

Celldex (NASDAQ: CLDX) announced that its Phase 2 study of barzolvolimab for prurigo nodularis (PN) failed to meet its primary and key secondary endpoints, despite successfully depleting mast cells. The company is discontinuing the PN program based on these results, which suggested that mast …

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Celldex reported that its Phase 2 study of barzolvolimab for prurigo nodularis (PN) did not meet its primary or key secondary efficacy endpoints, leading the company to discontinue the study for this indication. Despite profound mast cell depletion in PN patients, there was no …

Celldex to stop skin disease study after trial setback

Celldex Therapeutics announced it would discontinue development of its experimental drug barzolvolimab for prurigo nodularis after it failed to meet primary and secondary goals in a mid-stage study. This setback sent the company's shares down over 7% in extended trading. Despite the drug effectively …

Guggenheim raises Celldex stock price target on trial outlook By Investing.com

Guggenheim has increased its price target for Celldex Therapeutics (NASDAQ:CLDX) shares to $100 from $90, maintaining a Buy rating due to the promising outlook for its drug, barzolvolimab. The firm's analysis, ahead of the pivotal EMBARQ-CSU1/2 trial results expected in October 2026, projects approximately …

Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44, Maintains Overweight Rating

Morgan Stanley has revised its price target for Celldex Therapeutics (NASDAQ:CLDX) to $40, down from the previous $44. Despite this adjustment, the firm has decided to maintain its Overweight rating on the stock.

Celldex CFO Sam Martin to Retire; Company Begins Search for Successor

Celldex Senior Vice President and Chief Financial Officer Sam Martin announced his retirement, effective on or about March 31, 2027. The company has initiated a search for his successor. Martin joined Celldex in April 2009 and has served as CFO since July 2017.

Celldex Starts CFO Search as Martin Plans 2027 Retirement

Celldex (NASDAQ:CLDX) announced that its Senior Vice President and Chief Financial Officer, Sam Martin, plans to retire in March 2027. Martin, who has served as CFO since 2017 and has been with Celldex since 2009, will remain in his role during the search for …

Celldex CFO Sam Martin to retire in March 2027 By Investing.com

Sam Martin, Celldex Therapeutics' Senior Vice President and Chief Financial Officer, announced his retirement effective March 2027. Martin has been with the company's finance team since 2009 and served as CFO since 2017, overseeing a period of strong financial health. Celldex, which develops antibody-based …

Celldex Announces Planned Transition of Chief Financial Officer

Celldex announced that Sam Martin, Senior Vice President and Chief Financial Officer, plans to retire in 2027. Mr. Martin, who has been with Celldex since 2009 and CFO since 2017, will remain in his role until March 2027 to ensure a smooth transition while …

Celldex Therapeutics (NASDAQ: CLDX) CFO to retire around March 2027

Celldex Therapeutics announced that its Senior Vice President and Chief Financial Officer, Sam Martin, plans to retire around March 31, 2027. Martin, who has been with the company since 2009 and CFO since 2017, will remain in his role until his successor is appointed …

Celldex Therapeutics, Inc. Announces Retirement of Sam Martin as Chief Financial Officer, Effective on or About March 31, 2027

Celldex Therapeutics, Inc. announced that Sam Martin, their Senior Vice President and Chief Financial Officer, plans to retire around March 31, 2027. Martin has been with Celldex since 2009 and served as CFO since 2017. The company has initiated a search for his successor, …

Celldex Therapeutics, Inc. Actuals & Estimates (NASDAQ:CLDX)

CLDX Forecast — Price Target — Prediction for 2027

CLDX Q1 2026 Earnings: Celldex Reports EPS Miss Amid Early-Stage Pipeline Progress - Forward Guidance Trends

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates

Celldex Therapeutics Rallied 24% After Clinical Update: Here’s What Analysts See Next

Celldex Therapeutics (CLDX) Stock Price, News & Analysis

Celldex Therapeutics Inc. (CLDX) News, Articles, Events & Latest Updates

Celldex Therapeutics, Inc. (CLDX) Stock Price, News, Quote & History